Decision Resources, Inc., announces the publication of Type 2 Diabetes Mellitus, a multiclient study that offers a ten-year market outlook for current and emerging therapies in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan).

(Photo: )

Specialists interviewed for this study report that while medical practice varies greatly among countries, the most important goal is glycemic control. The United Kingdom Prospective Diabetes Study (UKPDS) verified the clinical significance of tight glycemic control for reducing microvascular complications, as well as macrovascular ones. Some physicians believe that medical practice is shifting in favor of the biguanide metformin (Lipha/Bristol-Myers Squibb's Glucophage, generics), which is benefiting from its strong performance in the UKPDS and greater recognition of its secondary, insulin-sensitizing mode of action. Physicians also anticipate the gradual adoption of rosiglitazone (SmithKline Beecham's Avandia) and pioglitazone (Takeda's Actos) as first-line therapies. A major ongoing debate surrounds the treatment of early-stage type 2 diabetes, because physicians often find it difficult to determine how insulin resistant, versus insulin deficient, a patient is.

Seven-market sales of type 2 diabetes drugs totaled approximately $4.6 billion in 1998 and are expected to grow 10% per year during the first half of our forecast period, reaching $7.5 billion in 2003. Market expansion will be driven primarily by double-digit annual growth rates of three drug classes: biguanides, thiazolidinediones, and meglitinides. Inhaled insulin formulations, if approved, will have the potential to generate significant sales.

Type 2 Diabetes Mellitus is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Contact: Contact: Frank Sama, 781.487.3753 (telephone), 781.487.5750 (fax), or (e-mail). In Europe, contact Ms. Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or (e-mail). In Japan, contact Ms. Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or (e-mail).

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing industry trends in the international health care and pharmaceutical industries.


AP Archive:

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc, 781-487-3753,

Arrhythmias Represent an Area of Untapped Potential in Cardiovascular Drug Development, According to a New Decision Resources Study

View Now